1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Spinal Cord Injury Research Program (SCIRP) Anticipated Funding Opportunities for Fiscal Year 2026 (FY26) is sponsored by Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP). The SCIRP funds research and development efforts to advance the treatment and management of spinal cord injury (SCI) and ameliorate its consequences.
The program emphasizes the involvement of individuals with lived SCI experience in the research process.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the funder's official program page to help you evaluate fit faster.
Press Release: 2026 Spinal Cord Injury Research Program, Congressionally Directed Medical Research Program You are using an outdated browser. Please upgrade your browser to improve your experience. U.S. Department of War organization.
Lapse in Federal Appropriations The most recent appropriations for the Department of War expired at 11:59 p. m. EST on September 30, 2025.
Military personnel will continue in a normal duty status without pay until such time as a continuing resolution or appropriations are passed by Congress and signed into law. Civilian personnel not engaged in excepted activities will be placed in a non-work, non-pay status. Visit www.
dha. mil/shutdown for more information.
DEPARTMENT OF WAR - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS Transforming Health Care through Innovative and Impactful Research 2026 Spinal Cord Injury Research Program Released: February 17, 2026 Defense Health Agency Research and Development Medical Research and Development Command Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program For FY26, the SCIRP identified near-term and long-term goals for program-supported research outcomes and products, which align to four key priority areas within the SCI field.
Research supported by the FY26 SCIRP must address at least one of the program priority areas and an associated near-team goal listed below. Additionally, applications must describe the steps the research team will take to further advance the research outcome/product in accordance with the long-term goal of the same priority area.
Priority Area: Acute Injury Intervention Near-Term Goal: Develop and test interventions, e.g., surgical, device, pharmacologic, to preserve and/or protect spinal cord tissue within a clinically feasible timeframe for improved neurologic outcomes relevant to the civilian and/or battlefield/deployed environment Long-Term Goal: Adoption of acute SCI management/stabilization practices within the battlefield, pre-hospital or hospital environments that meaningfully improve outcomes Priority Area: Secondary Health Effects Near-Term Goal: Develop and test interventions to address secondary health effects of SCI that impact injury survivors throughout their full lifespan Long-Term Goal: Adoption of interventions that address secondary health effects of SCI Priority Area: Psychosocial issues Near-Term Goal: Develop and test interventions that address psychosocial issues and that are specifically tailored for people with SCI, their families and/or their care-partners.
Long-Term Goal: Adoption of interventions that promote psychosocial well-being for people with SCI, their families and/or their care-partners.
Priority Area: Rehabilitation and Regeneration Near-Term Goal A: Develop and test rehabilitation strategies that meaningfully improve functional recovery after SCI Near-Term Goal B: Develop and test regenerative/neuroplastic interventions that meaningfully improve outcomes after SCI Long-Term Goal: Adoption of interventions/techniques that meaningfully improve outcomes after SCI Independent investigators at all career levels.
Early-Career Partnership Option Requires one early-career investigator to partner with one independent investigator at any career level. Early-career investigators are individuals with at least 3 years of independent or non-independent research experience beyond a terminal degree but no more than 7 years within their first faculty appointment or equivalent independent research position.
The early-career investigator may serve as the initiating or partnering PI. Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of SCI. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant populations.
Alternative trial designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial. Applications must name at least two community partners who will provide advice and consultation throughout the planning and implementation of the research project. Maximum period of performance is 4 years Maximum allowable funding is $4.
8 million for total costs* Early-Career Partnership Option Maximum period of performance is 4 years Maximum allowable funding is $4. 96M for total costs* Accommodates two PIs on seperate individual awards Clinical Translation Research Award Independent investigators at all career levels. Early-Career Partnership Option Requires one early-career investigator to partner with one independent investigator at any career level.
Early-career investigators are individuals with at least 3 years of independent or non-independent research experience beyond a terminal degree but no more than 7 years within their first faculty appointment or equivalent independent research position. The early-career investigator may serve as the initiating or partnering PI.
Supports high-impact, new or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot or optimization, to prepare for larger-scale clinical trials. Primary goals of this mechanism include: Advance Clinical Practice: Translate current and emerging techniques/interventions into clinical use by de-risking and informing the design of definitive trials.
Inform Decision-Making: Identify the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care-partners and policymakers. Applications must propose clinical research or clinical trials and may not propose animal research.
Applications must name at least two community partners who will provide advice and consultation throughout the planning and implementation of the research project. Maximum period of performance is 3 years Maximum allowable funding is $2. 0M for total costs* Early-Career Partnership Option Maximum period of performance is 3 years Maximum allowable funding is $2.
16M for total costs* Accommodates two PIs on seperate individual awards Translational Research Award Independent investigators at all career levels. Early-Career Partnership Option Requires one early-career investigator to partner with one independent investigator at any career level.
Early-career investigators are individuals with at least 3 years of independent or non-independent research experience beyond a terminal degree but no more than 7 years within their first faculty appointment or equivalent independent research position. The early-career investigator may serve as the initiating or partnering PI. Supports research to accelerate the movement of promising ideas in SCI research toward clinical application.
Applications may include preclinical animal studies and/or clinical research involving human subjects and human anatomical substances. May include a pilot clinical trial ONLY as a part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
Applications must name at least one community partner who will provide advice and consultation throughout the planning and implementation of the research project. Maximum period of performance is 3 years Maximum allowable funding is $2. 0M for total costs* Early-Career Partnership Option Maximum period of performance is 3 years Maximum allowable funding is $2.
16M for total costs* Accommodates two PIs on seperate individual awards Investigator-Initiated Research Award Independent investigators at all career levels. Early-Career Partnership Option Requires one early-career investigator to partner with one independent investigator at any career level.
Early-career investigators are individuals with at least 3 years of independent or non-independent research experience beyond a terminal degree but no more than 7 years within their first faculty appointment or equivalent independent research position. The early-career investigator may serve as the initiating or partnering PI.
Funds research with the potential to make an important contribution to SCI research, patient care and/or quality of life. Permitted research includes preclinical studies in animal models, research with human subjects or human anatomical substances, as well as ancillary studies associated with an existing clinical trial. Preliminary data required.
Clinical trials not allowed. Maximum period of performance is 3 years Maximum allowable funding is $800,000 for total costs* Early-Career Partnership Option Maximum period of performance is 3 years Maximum allowable funding is $960,000 for total costs* Accommodates two PIs on seperate individual awards *Total costs include direct and indirect costs. dha.
detrick. cdmrp. mbx.
public-affairs@health. mil Last updated Tuesday, February 17, 2026
According to the current listing, eligibility includes: Not explicitly detailed in the snippet, but CDMRP grants are typically open to academic, government, and private sector organizations. Confirm the full requirements in the official notice before applying.
Spinal Cord Injury Research Program (SCIRP) Anticipated Funding Opportunities for Fiscal Year 2026 (FY26) is funded by Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
CDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article